2015 510(k) Clearances
This article was originally published in The Gray Sheet
A sortable and searchable table of 510(k)s cleared by FDA in 2015, updated monthly. Latest update: Clearances through Oct. 31.
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.